在帕金森病患者中使用LSVT®Coach进行面对面和在线LSVT®LOUD语音训练的比较:试点随机对照试验
Elisabeth Kratz1,2, Judith Scheffer3, Dieter Volc4
1Center for Neurorehabilitation, Department for Clinical Neurosciences and Preventive Medicine, University for Continuing Education Krems, Krems, Austria.
BMC neurology
|April 26, 2025
概括
LSVT® LOUD 远程治疗和传统的 LSVT® LOUD 治疗对帕金森病有效.
科学领域:
- 语音语言病理学 语言病理学
- 神经学 神经学
- 远程医疗远程医疗
背景情况:
- LSVT® LOUD是一种密集的语音治疗,用于帕金森病 (PD) 中的语音振幅,并具有低动力性失联症.
- 这项研究将LSVT® LOUD远程治疗 (LSVT® LOUD-tele) 与传统面对面的LSVT® LOUD治疗 (LSVT® LOUD-FTF) 相比较.
- 该研究还评估了LSVT® LOUD-tele软件的可用性,以及全面随机对照试验 (RCT) 的可行性.
研究的目的:
- 为了研究LSVT® LOUD-tele与LSVT® LOUD-FTF在患有PD和低动力性失节症的个体中的初步效应.
- 评估LSVT® LOUD-tele的可用性和可行性,用于未来的大规模研究.
主要方法:
- 一项试点随机对照试验 (RCT) 参与了20名患有PD和低动力性关节障碍症的参与者.
- 参与者被分配到LSVT® LOUD-tele或LSVT® LOUD-FTF中,每周有4次60分钟的会议持续4周.
- 主要结局:声音的响亮度 (音压水平[SPL]). 二次结果:语音障碍,生活质量 (QoL) 和抑郁症.
主要成果:
- 无论是LSVT® LOUD-tele还是LSVT® LOUD-FTF,在特定的语音声音强度测量和文本阅读方面都有所改善.
- 在这两组中,主观语音障碍得到改善;LSVT® LOUD改善了整体与失联症相关的QoL.
- LSVT® LOUD-tele表现出良好的至优秀的可用性,试点研究支持了全面RCT的可行性.
结论:
- 两种LSVT® LOUD-tele和LSVT® LOUD-FTF似乎都有效改善PD和低动力性失联症患者的声音.
- 远程治疗方法对于进行更大规模的临床试验是可用的和可行的.
- 建议通过更大规模的研究进行进一步的研究,以验证这些发现.
相关概念视频
Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
Parkinson's Disease: Overview
308
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
308


